|Description||Elafibranor is a dual PPARα/δ agonist. Elafibranor increases plasma HDL and expression of Acox1, a PPARα target gene, and decreases plasma triglycerides and total cholesterol in the liver of ApoE2-KI wild-type mice. Elafibranor is identified as a drug candidate for the treatment of cardiometabolic diseases such as diabetes, insulin resistance, dyslipidemia, and non-alcoholic fatty liver disease (NAFLD).|
|B0084-074234||250 mg||$299||In stock|
|Brife Description||PPARα/δ agonist|
|Synonyms||GFT-505; GFT505; 2-[2,6-dimethyl-4-[(E)-3-(4-methylsulfanylphenyl)-3-oxoprop-1-enyl]phenoxy]-2-methylpropanoic acid|
|Application||potential treatment of cardiometabolic diseases|
Parstatin, a 41-mer peptide which is cleaved upon activation of Proteinase-Activated Receptor 1, attenuates endothelial cell migration and proliferation (IC50 ~...
A potent PPARα modulator
CP 775146 is a high affinity PPARα agonist and show hypolipidemic activity in vivo.
Muraglitazar is a peroxisome proliferator-activated receptor (PPAR) α/γ dual agonist(EC50s = 320 and 110 nM in vitro).
FH535 sodium salt is a dual inhibitor of peroxisome proliferator-activated receptor (PPAR) and Wnt/β-catenin/TCF/LEF signaling. FH535 inhibits recruitment of th...
Lanifibranor is a peroxisome proliferator-activated receptors (PPAR) agonist.
GSK7227 is a novel class of PPARdelta partial agonists. It shows potent partial agonism of the PPARdelta target genes CPT1a and PDK4 in skeletal muscle cells.
MCC-555, a thiazolidinedion derivative, has been found to be a PPAR agonist that was once studied as hyperglycaemic and hyperlipidaemic. The Phase II trial agai...
MHY 908 is a dual PPARα/γ agonist and a melanogenesis inhibitor that suppresses mushroom tyrosinase activity (IC50 value 8.19 μM). MHY908 exhibits more potent a...
A potent, tyrosine-based peroxisome proliferator-activated receptor γ (PPARγ) agonist (EC50 = 13 nM for murine receptor and 6.2 nM for human receptor in cell-ba...
Fenofibrate (Tricor, Trilipix) is a compound of the fibrate class and fibric acid derivative.It is used alone or along with statins in the treatment of hypercho...
GSK0660 is a selective PPARδ antagonist. GSK0660 blocks the effect of TNFα on the expressions of cytokines involved in leukocyte recruitment, including CCL8, CC...
Gemfibrozil is the generic name for an oral drug used to lower lipid levels. It belongs to a group of drugs known as fibrates. It is most commonly sold as the b...
Inolitazone is an orally bioavailable PAPR-gamma inhibitor with potential antineoplastic activity. Inolitazone binds to and activates peroxisome proliferation-a...
Oleylethanolamide is an endogenous agonist for PPARα with an EC50 value of 120 nM in a transactivation assay. Oleylethanolamide is also a selective GPR55 agonis...
LY518674, a phenoxypropionic acid derivative, is a Potent and selective PPAR-alpha agonist produced a dose-dependent increase in serum HDL-c, resulting in 208 +...
Saroglitazar magnesium is a dual PPAR agonist with potent predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, res...
CDDO Imidozolide is a synthetic triterpenoid as Nrf2 signaling activator with highly active in suppressing cellular proliferation of human leukemia and breast c...
GW501516 is a potent and highly selective PPARβ/δ agonist, with EC50 of 1 nM, with 1000-fold selectivity over hPPARα and hPPARγ. Phase 4.
Elafibranor is a dual PPARα/δ agonist. Elafibranor increases plasma HDL and expression of Acox1, a PPARα target gene, and decreases plasma triglycerides and tot...